IRVINE, Calif., Sept. 13, 2005 (PRIMEZONE) -- "Recent acquisitions by industry leaders in the biotechnology and pharmaceutical industries affirms what is becoming more and more obvious - big companies need more technology, more products in the pipeline," stated SmallCap Sentinel analyst D.R. Clark. "The expiration of patents and loss of major revenue-earning drugs to litigation makes these moves imperative."
"Companies cannot stand pat with static research and development pipelines. With the aging Baby Boomer market a cash cow waiting to happen for bio and pharma companies, it's time to load up the shelves," Clark added. "Pity be the company that doesn't aggressively target technology in pharmaceuticals, stem cell research, medical devices, and more. They could well be on the outside looking in."
The informational reports "Innovations in Biotechnology" and "Looking at the Political Impact on Stem Cell Research" have been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The reports will detail various issues affecting the current market for biotechnology companies including New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European stem cell research & development with Western management, Merck (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and GlaxoSmithKline PLC (NYSE:GSK).
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.